ESM Table 4 Treatment emergent serious adverse events preferred term, occurring in more than one subject, ITT

	Detemir			Glargine		
	n	(%)	E	*n*	(%)	E
ITT analysis set	291			291		
Adverse event	42	(14.4)	47	53	(18.2)	73
Coronary artery disorder	2	(0.7)	2	6	(2.1)	6
Myocardial infarction	3	(1.0)	3	0	(0.0)	0
Back pain	0	(0.0)	0	2	(0.7)	2
Chest pain	2	(0.7)	2	4	(1.4)	6
Carcinoma	3	(1.0)	3	0	(0.0)	0
Pneumonia	2	(0.7)	2	1	(0.3)	1
Injury accidental	2	(0.7)	2	3	(1.0)	3
Cerebrovascular disorder	1	(0.3)	1	5	(1.7)	5
Peripheral ischaemia	1	(0.3)	1	2	(0.7)	2
Hypoglycaemia	2	(0.7)	2	3	(1.0)	3
Arthrosis	1	(0.3)	1	2	(0.7)	2
Fracture pathological	0	(0.0)	0	2	(0.7)	2
Cardiac failure	0	(0.0)	0	2	(0.7)	2
Cholelithiasis	0	(0.0)	0	3	(1.0)	3
Anaemia	0	(0.0)	0	2	(0.7)	2

ITT analysis set consists of all subjects exposed to trial product
E, number of adverse events; *n*, number of subjects with adverse event; %, proportion of subjects in analysis set who experienced adverse event